‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say
Executive Summary
PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.
You may also be interested in...
Costs From ICER’s Unsupported Price Increase List Tick Back Up
Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.